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Abstract29
The administration of recombinant methionyl bovine somatotropin (rMbST) to dairy cows to 30
increase milk yield remains a common practice in many countries including the USA, Brazil, 31
Mexico, South Africa and Korea, whereas it has been forbidden within the European Union 32
(EU) since 1999. A rapid screening immunoanalytical method capable of the unequivocal 33
determination of rMbST in milk would be highly desirable in order to effectively monitor 34
compliance with the EU-wide ban for home-made or imported dairy products. For decades, 35
the production of specific antibodies for this recombinant isoform of bovine somatotropin 36
(bST) has remained elusive, due to the high degree of sequence homology between both 37
counterparts (e.g. methionine for rMbST in substitution of alanine in bST at the N-terminus). 38
In this study, we compared several immunizing strategies for the production of specific 39
polyclonal antibodies (pAbs), based on the use of the full-length recombinant protein, an 40
rMbST N-terminus peptide fragment and a multiple antigen peptide (MAP) which consists of 41
an oligomeric branching lysine core attached to the first two N-terminus amino acids of 42
rMbST, methionine and phenylalanine (MF-MAP). The immunization with KLH-conjugated 43
MF-MAP led to the production of the pAb with the highest rMbST/bST recognition ratio 44
amongst the generated battery of antibodies. The pAb exhibited a specific binding ability to 45
rMbST in a competitive antigen-coated ELISA format, which avidity was further improved 46
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after purification by rMbST N-terminus peptide-based affinity chromatography. These results 47
suggest that immunodiscrimination between structurally related proteins can be achieved 48
using immuno-enhanced immunogens such as MAPs.49
50
Keywords: recombinant methionyl bovine somatotropin, polyclonal antibodies, 51
immunodiscrimination, multiple antigen peptide.52
53
Abbreviations: bST, bovine somatotropin; rMbST, recombinant methionyl bovine 54
somatotropin; MAP, multiple antigen peptide; pAb, polyclonal antibody.55
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1. Introduction57
Bovine somatotropin (bST), with the majority isoform of 191-amino acid protein and a 58
molecular weight of 21802 Daltons (Table 1), is produced and secreted by the anterior 59
pituitary gland. Through a complex network system, the somatotropic axis, this hormone 60
regulates several physiological processes involved in metabolism, growth and reproduction 61
[1]. It is well documented that the exogenous administration of bST redirects nutritional 62
partitioning towards milk synthesis in dairy cows, which is therefore translated into an 63
increase in milk production ranging from 10 to 40% [2,3]. Genetically-engineered or 64
recombinant isoforms of the bovine somatotropin have been developed and produced since 65
the early 1990’s. Recombinant methionyl bST (rMbST; Table 1), initially commercialized by 66
Monsanto and then by Elanco (Animal Division of Eli Lilly and Company) under the trade 67
name of Posilac®, is the only commercial product approved by the Food and Drug 68
Administration (FDA) in the USA and by the corresponding competent authorities in Brazil, 69
Mexico, South Africa and Korea. However, its marketing and utilization as well as the trade 70
of dairy products obtained from rMbST-treated animals, are prohibited within the EU [4], and 71
other countries such as Japan, China, Australia, New Zealand or Canada. Along with the on-72
going hormone debates between the EU and the USA, controversy has surrounded rMbST 73
since it became commercially available in 1994, with growing concern about the implications 74
of the administration of this synthetic protein on human and animal health and welfare. 75
Several adverse effects reported for treated animals include diminished fertility and an 76
increased occurrence of lameness and clinical mastitis [5, 6], which requires additional 77
antibiotic treatments that may cause further food safety concern regarding antibiotic residues 78
in dairy and other food products. Extensive use of antibiotics in modern agricultural farming 79
has also been linked to the development and emergence of antibiotic resistance that is 80
currently affecting both human and veterinary medicine worldwide [7]. Moreover, 81
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administration of somatotropin raises the concentration of Insulin-like Growth Factor 1 (IGF-82
1) in milk [8]. Elevated circulating levels of IGF-1 have been associated with a higher risk of 83
developing several types of cancer [9, 10]. However, studies correlating the intake of milk 84
from rMbST-treated animals with human diseases are still lacking.85
In order to control illegal administration of rMbST and to ensure high quality and safety of 86
milk and consumer protection, reliable analytical methodologies capable of unambiguous 87
identification of the synthetic methionyl growth hormone in milk are required. Current 88
analytical methods for determination of rMbST rely on instrumental technologies such as 89
HPLC-MS/MS [11-14]. Despite the fact that chromatographic systems are highly sensitive 90
and specific, these techniques often limit their applications for rapid screening of a large 91
number of samples due to the requirement of extensive sample preparation time and 92
sophisticated instrumentation which is also laboratory-based. Immunoanalytical methods, in 93
particular Enzyme-Linked Immunosorbent Assays (ELISA), are widely used as rapid 94
screening tools for routine monitoring of food contaminants and residues, owing to their 95
simplicity, cost-effectiveness and capabilities of performing high-throughput analysis. Two 96
different immunoanalytical approaches have been adopted for the detection of rMbST. By the 97
direct strategy, the presence of the native and the recombinant isoforms is determined 98
simultaneously in biological fluids [15-17], whereas the indirect approach is based on the 99
analysis of biomarkers of which their concentration is increased upon rMbST administration. 100
IGF-1 has been the traditional target measured for this purpose [8, 17-20]. Methods based on 101
the detection of anti-rMbST immunoglobulins in treated cows have also been published [21, 102
22]. Nevertheless, the direct analysis of rMbST itself is highly preferable, in order to 103
circumvent problems associated with inter and intra-individual variation of biomarkers 104
expression levels, which can lead to misinterpretation of results. 105
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To date, no specific immunoassays have been described for the detection of rMbST. The high 106
sequence homology displayed by the recombinant and the native somatotropins (methionine 107
in substitution of alanine at the N-terminus) has greatly hindered the successful production of 108
rMbST-selective antibodies. The strategy most often used entails the immunization with the 109
complete recombinant protein [21, 23-25]. Nevertheless, the antibodies produced following 110
this procedure have generally failed in their capacity to immunodiscriminate between bST 111
and rMbST, while a 2–fold increased affinity factor towards rMbST was described for the 112
mAb-based sandwich assay developed by Erhard et al [23]. Considering that only one amino 113
acid of difference at the N-terminus is encountered, the immunization with the whole protein 114
most likely leads to the production of antibodies directed towards shared epitopes in both 115
counterparts, bST and rMbST, therefore being unable to specifically recognize the latter. On 116
the other hand, a frequently accomplished practice for raising antibodies against proteins is 117
based on the use of immunizing synthetic peptide fragments which mimic concrete sequences 118
within the target [26-28]. The immunization with a synthetic peptide representing the 119
differential N-terminus of rMbST could a priori focus the immune response towards the 120
recognition of the characteristic epitope of the protein. Castigliego et al described for the first 121
time the production of a mAb by using a synthetic nine amino acid rMbST N-terminus-122
mimicking peptide coupled to KLH as immunogen [16]. Despite showing a 3–fold higher 123
affinity towards rMbST than to bST, complete immunodiscrimination was not yet possible by 124
using the developed immunoassays. As an alternative to monovalent peptides, multiple 125
antigen peptides (MAPs) or multimerized peptides, have been used as immunogens since 126
they were developed in 1988 [29], especially in the area of vaccine development [30-32]. 127
MAPs have been shown to efficiently improve the immunogenicity of a particular antigen, 128
thus eliciting a stronger immune response, as a consequence of the presentation of multiple 129
copies to the immune system [33]. Furthermore, it has been reported that the resulting130
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immune response is generally mono-specific and more homogeneous [34]. The production of 131
pAbs targeted at vertebrate somatotropins using a synthetic MAP constituted by several 132
copies of an 18 amino acid highly conserved domain proximal to the C-terminus of the 133
protein has already been published [35]. To our knowledge this system has never been 134
applied before for the production of rMbST-specific antibodies. 135
In the present work several immunization strategies have been compared for the production 136
of anti-rMbST rabbit pAbs. The immunization with an octavalent synthetic rMbST N-137
terminus dipeptide-mimicking MAP, followed by affinity purification with a synthetic 138
rMbST N-terminus-mimicking linear peptide, resulted in the production of a pAb capable of 139
specifically differentiating between the recombinant and the native somatotropins in a 140
competitive ELISA format.      141
2. Experimental142
2.1. Reagents and instrumentation143
3-(cyclohexylamino)-1-propanesulfonic acid (CAPS), 2-(N-morpholino)ethanesulfonic acid, 144
2-(4-morpholino)ethanesulfonic acid (MES), 1-ethyl-3-(3-dimethylaminopropyl) 145
carbodiimide (EDC) and N-hydroxysuccinimide (NHS) were obtained from Sigma Aldrich 146
(St. Louis, MO, USA). Succinimidyl 4-[N-maleimidomethyl]cyclohexane-1-carboxylate 147
(sulfo-SMCC) was acquired from Thermo Fisher Scientific (Rockford, IL, USA). Slide-A-148
Lyzer dialysis cassettes and Zeba 7kDa Desalting columns from Thermo Fisher Scientific 149
(Rockford, IL, USA) were used for the purification of the immunizing conjugates. Keyhole 150
limpet hemocyanin (KLH) carrier protein, complete and incomplete Freund’s Adjuvants, the 151
bicinchoninic acid (BCA) test kit were from Sigma Aldrich (St. Louis, MO, USA). rMbST N-152
terminus dipeptide-mimicking MAP, MF-MAP-C (Figure 1), was acquired from GenScript 153
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(Piscataway, NJ, USA). Synthetic rMbST N-terminus-mimicking linear peptides EP091213 154
(amino acid sequence: H2N–Met-Phe-Pro-Ala-Met-Ser-Leu-Ser-Gly-Leu-Phe-Ala-Asn-Ala-155
Val-Leu-Arg-Cys–COOH) and EP093536 (amino acid sequence: H2N–Met-Phe-Pro-Ala-156
Met-Ser-Leu-Ser-Gly-Leu-Phe-Cys–CONH2), used for animal immunization and antibody 157
purification, respectively, were purchased from Eurogentec S.A. (Seraing, Belgium). Affinity 158
columns packed with Protein A Sepharose 4 Fast Flow gel purchased from GE Healthcare 159
were used for the purification of rabbit antibodies. EP093536 peptide affinity column was 160
prepared using Toyopearl AF-Amino-650M gel from Tosoh Bioscience GmbH (Stuttgart, 161
Germany). Maleimidobenzoic acid N-hydroxysuccinimide ester (MBS) and streptavidin 162
poly−HRP (STV−pHRP) were acquired from Thermo Fisher Scientific (Rockford, IL, USA). 163
Centricon Plus-20 ultracentrifugation concentration devices (molecular cut-off 3K) were 164
purchased from Millipore (Billerica, MA, USA). Peroxidase-conjugated polyclonal goat anti-165
rabbit immunoglobulin (GAR−HRP) was purchased from Sigma Aldrich. Biotin-SP-166
conjugated polyclonal goat anti-rabbit IgG (H+L) (GAR−b) was obtained from Jackson 167
Immunoresearch Europe (Suffolk, United Kingdom). Gelatin was from Merck (Darmstadt, 168
Germany). Bovine serum albumin (BSA) was from Sigma Aldrich. Lactoferrin from bovine 169
milk was provided by Taradon Laboratory SPRL (Tubize, Belgium). β-lactoglobulin from 170
bovine milk was from Sigma Aldrich. Casein from bovine milk was purchased from Merck. 171
Bovine prolactin was from the National Institute of Health (NIH, USA). Bovine placental 172
lactogen was provided by Jean-François Beckers from the University of Liège (Liège, 173
Belgium). Pepstatin, EDTA and acetic acid were from Sigma Aldrich (St. Louis, MO, USA). 174
Sequencing-grade modified trypsin (EC 3.4.21.4) was from Promega (Madison, WI, USA). 175
Ninety-six-well flat-bottom Nunc Maxisorp polystyrene ELISA plates were purchased from 176
Nunc (Roskilde, Denmark). ELISA plate washer model 1575 Immunowash was from Bio-177
Rad Laboratories (Hercules, CA, USA). 3,3’,5,5’-Tetramethylbenzidine/H2O2 solution was 178
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from BioFX Laboratories (Owings Mills, MD, USA). ELISA absorbance was monitored at 179
450 nm using a Multiskan EX reader provided by Thermo Fisher Scientific (Zellik, Belgium). 180
Buffers and solutions:  1) Coating buffer (CB): 50 mM sodium carbonate–bicarbonate buffer 181
(pH 9.6). 2) Blocking solution: CB containing 0.5% (w/v) gelatin. 3) EIA buffer: 5.6 mM 182
Na2HPO4·2H2O, 0.9 mM NaH2PO4·2H2O, 150 mM NaCl, (pH 7.4), containing 0.02% (w/v) 183
gelatin, 0.005% (v/v) Tween 20, 0.001% (w/v) 8-Anilino-1-naphthalenesulfonic acid 184
ammonium salt, 0.005% (w/v) ascorbic acid, 0.01% (w/v) thimerosal. 4) Washing solution: 185
150 mM NaCl, containing 0.05% (v/v) Tween 20. 5) PBS: 44 mM sodium phosphate, 6 mM 186
potassium phosphate, 154 mM NaCl, (pH 7.4). 6) PBST: PBS containing 0.05% (v/v) Tween 187
20.188
2.2. Somatotropin standards189
Pituitary bovine somatotropin (bST) was purchased from the National Hormone and Peptide 190
Program (NHPP), Harbor-UCLA Medical Centre (Torrance, CA, USA). Pituitary porcine 191
somatotropin (pST) was from Sigma Aldrich. Recombinant methionyl equine somatotropin 192
(rMeST, EquiGen-5) was from Bresagen Ltd. (Thebarton, Australia). Recombinant methionyl 193
bovine somatotropin (rMbST) was extracted from the slow release formula of Lactotropin® 194
syringes provided by Elanco (Greenfield, IN, USA) as described previously with 195
modifications [25]. Briefly, 20 mL of 50 mM CAPS buffer (pH 11.0; 100 mM NaCl) was 196
added to 500 mg of syringe content. The syringe content was emulsified by vortex for 1 197
minute and then by sonication for 10 minutes in a water bath.  The emulsion was immediately 198
centrifuged (1000×g, 10 min) and the transparent layer containing rMbST was removed from 199
the white excipient layer. To ensure maximum recovery of rMbST a further 10 mL of CAPS 200
buffer was emulsified with the remaining white excipient and mixed by vortex and sonication 201
and centrifuged as previously described. The rMbST phases were pooled together and filtered 202
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using a 0.45 µm cellulose filter. The rMbST solution was immediately aliquoted, lyophilized 203
and stored at –20 °C until use. The protein concentration of the extracted rMbST was 204
determined using a BCA assay and confirmed by liquid chromatography coupled to high-205
resolution mass spectrometry measurement (LC-HRMSn; results not shown), as described 206
previously [11]. A tryptic digestion was performed overnight at 37 °C in 120 µL of 50 mM 207
ammonium bicarbonate, 10 mM EDTA and 1 µM pepstatin (pH 7.9) with 2 µg of enzyme. 208
The extracts were then evaporated, reconstituted in 40 µL of water/acetonitrile 70:30 (v/v) 209
with 0.2% (v/v) formic acid and analyzed by LC-HRMSn. Separation of the peptides was 210
achieved on a Symmetry 300 2.1 mm × 150 mm C4 column packed with 3.5 µm beads, 300 211
Å pore size (Waters, Milford, USA) . The solvent flow rate was set at 300 µL min-1. Peptides 212
were separated using acetonitrile containing 0.2% (v/v) formic acid (A) and water containing 213
0.2% (v/v) formic acid (B) as mobile phase. The elution gradient started with 10% A 214
increasing to 50% in 5 min, then decreasing to initial conditions in 5 min and remaining at 215
10% A for 5 more minutes. A divert valve was used to let the sample pass into the instrument 216
from 4.5 to 9 min. The typical expected retention time was 6.7 and 6.9 min for the rMbST N-217
terminus peptide and the rMeST N-terminus peptide (used as internal standard), respectively. 218
The MS instrument was a linear ion trap coupled to an orbitrap allowing high resolution 219
measurements (LTQ-OrbitrapTM, Thermo Electron, Bremen, Germany), fitted with an 220
electrospray ion source (ESI). The API interface was operated in positive ion mode. A sample 221
volume of 20 µL was loaded onto the column using the autosampler. A column heater was 222
used to ensure a stable column temperature of 30 °C. Mass spectrometric analyses were 223
performed in the following working conditions: capillary voltage was set at 42 V, source 224
voltage at 5 kV and capillary temperature at 300 °C. Nitrogen was used as sheath, auxiliary 225
and sweep gas at flow rates of 50, 10 and 10 (arbitrary unit), respectively. The linear ion trap 226
mass spectrometer was set to select the ions 933.5 and 913.3 corresponding to [M+2H]2+ of 227
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the tryptic N-terminus peptides of rMeST and rMbST, respectively. Collision energy of 20% 228
(arbitrary unit) was applied to the ion 933.5 and 18% to the ion 913.3. The detection of the 229
resulting product ions was performed in the orbitrap at a resolution of 30 000. Acquisition 230
was performed in full scan mode from m/z 500 to 1500. Data were collected and analyzed231
with the Xcalibur software (Thermo Electron).232
2.3. Preparation of immunogens233
i) Coupling of rMbST to KLH: the immunogen rMbST–KLH was obtained using the 234
EDC/NHS reaction. Briefly, 20 mg of EDC and 10 mg of NHS were dissolved in 100 μL of 235
0.05 M MES, 0.5 M NaCl buffer (pH 4.7). The solution of EDC/NHS was added to 10 mg of 236
rMbST and allowed to react for 10 min. The EDC/NHS-activated rMbST was added slowly 237
with stirring to 1 mL of PBS (pH 7.4) containing 20 mg of the carrier protein. The 238
conjugation reaction was performed overnight under stirring at room temperature.239
ii) Coupling of cysteine-containing rMbST N-terminus peptides to KLH: synthetic 240
rMbST N-terminus-mimicking peptides, EP091213 and MF-MAP-C (Figure 1), were 241
conjugated to KLH via their cysteine residues using the commercial sulfo-SMCC conjugation 242
kit (Fisher Scientific UK, Leicestershire, UK) according to manufacture instructions. 243
All of the immunogens were purified by overnight dialysis (Slide-A-Lyzer Dialysis cassettes; 244
3kDa cut-off) against a 0.9% (w/v) NaCl solution.  The protein concentration was estimated 245
by BCA assay and the conjugates were aliquoted, lyophilized and stored at −20 °C.246
2.4. Polyclonal antibody production247
Polyclonal antibodies were produced in New Zealand white SPF (specific pathogen free) 248
rabbits. A summary of the production of the pAbs is shown in Table 2. Rabbits were 249
immunized by subcutaneous injection with 1 mL of a 1:1 emulsion of a saline solution 250
containing the immunogen and Freund’s complete adjuvant (first dose) or Freund’s 251
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incomplete adjuvant (subsequent doses). Generally 0.2 mg of immunogen were administered, 252
with the exception of rMbST–KLH, for which 0.1 mg were used. Immunizations were 253
performed initially in intervals of 15 days, and then monthly after the third boost. A test 254
blood sample was obtained from every rabbit prior to immunization, and then 10 days after 255
each immunization from the 3rd boost onward. Pre-immune and immune sera were obtained 256
by coagulation and centrifugation of the blood samples. Working solutions were prepared in a 257
1:1 mixture of EIA buffer and ethylene glycol, and they were stored at –20 °C.   258
2.5. Peptide-based affinity purification of the polyclonal antibody MU11259
The pAb MU11 was purified by affinity chromatography using a peptide EP093536 column.260
i) Peptide EP093536 affinity column preparation: the –NH2 groups of the Toyopearl 261
AF-Amino-650M gel were activated with MBS, followed by the coupling of the maleimide 262
activated –NH2 moieties with the –SH group of the cysteine in the peptide EP093536. 2.5 mL 263
of gel in 1.25 mL of 50 mM sodium phosphate buffer (pH 6) were incubated for 30 min at 264
room temperature with orbital agitation with 175 µL of a MBS solution in N,N-265
dimethylformamide (DMF; 15 mg/mL). The gel suspension was then centrifuged (1800×g, 2 266
min) and supernatant was discarded. The gel was washed 3 times with 2.5 mL of 10× PBS 267
(pH 7.4), and resuspended in 1.25 mL of PBS. Immediately prior to use, the peptide 268
EP093536 (8.4 mg) was dissolved in 1.4 mL of a mixture of DMF:PBS (30:70, v/v). The 269
peptide solution was added to the gel suspension and incubated for 18 h at room temperature 270
under orbital agitation. After centrifugation, the gel was resuspended in 2.5 mL of PBS and 271
packed into a purification column. The peptide EP093536 affinity column was stored at 4 °C. 272
ii) Purification of the pAb MU11 by peptide-based affinity chromatography: prior to the 273
peptide-based purification, the immunoglobulin fraction of the rabbit pAb MU11 was isolated 274
from the crude serum (5 mL) by protein A affinity chromatography. The recovered 275
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immunoglobulin fractions were then dialyzed in PBS (18 h, 4 °C), and concentrated in a 276
Centricon Plus-20 device (4600×g, 30 min, 4 °C) up to a final volume of 1 mL. The solution 277
containing the immunoglobulins was loaded onto the peptide EP093536 column pre-278
conditioned by the addition of 5 volumes of PBS (20 g/L NaCl), and incubated at room 279
temperature for 3 h with orbital agitation. The non-retained immunoglobulins were eluted by 280
washing with PBS (20 g/L NaCl). The elution of the peptide-specific immunoglobulins was 281
conducted using 100 mM glycine buffer (pH 2.5). The column was regenerated by addition of 282
5 volumes of PBS and stored at 4 °C in 20:80 methanol:distilled water. Those fractions 283
containing immunoglobulins, as determined spectrophotometrically at 280 nm, were pooled 284
and dialyzed overnight in PBS containing 0.001% (w/v) NaN3 at 4 °C. The antibody 285
solutions (specific and non-specific fractions) were concentrated as described above, and the 286
concentration was estimated by the BCA protein assay test. The antibodies were stored at –20 287
°C in PBS containing 0.001% (w/v) of thimerosal and 10% (w/v) of BSA.288
2.6. Antigen-coated competitive ELISA289
i) General assay procedure: ELISA plates were coated overnight at room temperature 290
with 100 µL of the standard solution [rMbST or bST] prepared in coating buffer (ranging 291
from 0.25 to 16 µg/mL). The blocking of the plates was performed by incubation for 2 h at 37 292
°C with 250 µL of blocking solution. After the coating and the saturation steps, the plates 293
were aspirated. In the competitive assay, 50 µL of the antibody solution and 50 µL of the 294
standards prepared in EIA buffer were added and incubated for 1 h at 37 °C. Then, 100 µL of 295
labeled secondary antibody prepared in EIA buffer (GAR–HRP at 1:2000) was added and 296
incubated for 1 h at 37 °C. Plates were washed 5 times with washing solution between each 297
incubation step. Finally, the retained peroxidase activity was revealed with 100 µL of a 298
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ready-to-use TMB solution for 30 min in the darkness at room temperature. The enzymatic 299
reaction was stopped by addition of 50 µL of 1.8 N H2SO4. 300
ii) Optimized assay procedure: the following procedure was used for the purified pAb 301
MU11. This protocol was based on the general assay procedure, with slight modifications. An 302
overnight pre-incubation of the antibody and the antigen (mixed at equal volumes in plastic 303
tubes) was performed at 4 °C. Then, 100 µL of the pre-incubated solutions were added to the 304
coated and blocked plates, and incubated for 30 min at 37 °C. A biotin/streptavidin 305
amplification system was used, consisting of an initial incubation with 100 µL of a 1:150000 306
dilution of GAR–b prepared in PBST (1 h, 37 °C), followed by an additional incubation with 307
100 µL of a 1:20000 dilution of STV–pHRP prepared in PBST containing 1% (w/v) of BSA 308
(1 h, 37 °C).309
iii) Signal processing: Absorbance was monitored at 450 nm. The signal intensity was 310
plotted against the standard concentration in a logarithmic scale, and the resulting sigmoidal 311
curves were mathematically fitted to a four-parameter logistic equation using the SigmaPlot 312
software package from SPSS Inc. (Chicago, IL, USA). The IC50 value, corresponding to the 313
standard concentration that generates a 50% reduction of the maximum signal intensity 314
(Amax), was used for the estimation of the assay detectability. The limit of detection of the 315
assay (LOD) was determined as the concentration of standard that generates a 2sd decrease of 316
the signal obtained at the zero dose of analyte (A0 – 2sd). The absorbance values were 317
normalized using A0 as reference measure.318
2.7. Cross-reactivity study319
The capability of recognition by the peptide-purified antibody MU11 to pituitary bovine 320
somatotropin (bST), pituitary porcine somatotropin (pST), recombinant methionyl equine 321
somatotropin (rMeST), bovine serum albumin (BSA), lactoferrin, β-lactoglobulin, casein, 322
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bovine prolactin and bovine placental lactogen was evaluated by conducting competitive 323
experiments using the mentioned proteins as competitors. Cross-reactivity (CR) values were 324
calculated as follows: CR = IC50(rMbST)/IC50(competitor)×100.325
3. Results and discussion326
3.1. Immunogen description327
In the present work several immunizing strategies for the production of anti-rMbST 328
antibodies were compared. The immunogens were categorized as i) complete recombinant 329
somatotropin (rMbST); ii) rMbST N-terminus-mimicking synthetic linear peptide; and iii) 330
rMbST N-terminus-mimicking synthetic MAP. In the case of the synthetic molecules (linear 331
peptide and MAP), the design comprised a C-terminus cysteine, an amino acid commonly 332
introduced for coupling purposes, via the side chain thiol group. The rMbST-mimicking 333
synthetic linear peptide EP091213 represents the first 17 N-terminus amino acids of rMbST 334
(H2N–MFPAMSLSGLFANAVLRC–COOH). The rMbST-mimicking synthetic multiple 335
antigen peptide MF-MAP-C (Figure 1), displays in an arachnid-type manner eight units of 336
the first two N-terminus amino acids of rMbST, methionine and phenylalanine, with a weakly 337
immunogenic lysinen core. All of the immunogens were prepared by covalent conjugation of 338
the three mentioned molecules to the carrier protein KLH. In order to guarantee the 339
accessibility of the rMbST N-terminus characteristic portion of the antigens to the immune 340
system, different coupling chemistries were used for the preparation of the immunogens. In 341
the case of the recombinant whole protein, formation of amide bonds between the free 342
carboxylic groups of rMbST and the amine groups of KLH was conducted using the active 343
ester method. The peptide EP091213 and MF-MAP-C were conjugated using the 344
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heterobifunctional crosslinker sulfo-SMCC, by coupling each peptide to maleimide-activated 345
amine groups of KLH via the cysteine residue of their C-terminus.346
By the immunization of rabbits with the three mentioned immunogens, 9 polyclonal 347
antibodies were obtained (Table 2).348
3.2. Preliminary antibody characterization349
The capability of immunodiscrimination of the 9 available pAbs between the native and the 350
recombinant methionyl somatotropins was initially assessed by a checkerboard titration 351
procedure in the antigen-coated ELISA format using both proteins as coating antigens. As a 352
first approach, the crude sera were analyzed without any further purification. As shown in 353
Table 3, all three immunogens gave rise to a positive immune response. All of the antibodies, 354
with only one exception (M10), recognized the native somatotropin and/or the recombinant 355
methionyl isoform to a different extent. Despite immunization with rMbST–KLH generated 356
the pAbs with the highest titers, these were unable to immunodiscriminate the recombinant 357
methionyl isoform, therefore displaying a very similar binding behavior towards both 358
somatotropins. From these results and those described in previous studies where the same 359
immunizing strategy was used [21, 23-25], it could be inferred that using the complete 360
recombinant protein as immunogen directs the immune response towards common antigenic 361
determinants within the recombinant and the native isoforms, with the rMbST N-terminus 362
being “masked”. This remark is of special relevance in the case of pAbs, representing a 363
heterogeneous collection of antibodies with disparate profiles of selectivity, where the 364
rMbST-specific sub-population, if produced, would consequently be in the minority. Finally, 365
the immunogens consisting of rMbST N-terminus-mimicking synthetic peptides (both the 366
linear peptide and the MAP), afforded the most promising results, as three of the produced 367
pAbs exhibited a higher recognition towards rMbST, namely M9 for EP091213–KLH, and 368
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MU9 and MU11 for MF-MAP-SMCC–KLH. These antibodies were therefore selected for 369
further studies. 370
In order to reduce background-associated problems encountered with the raw sera, the three 371
pAbs were purified by protein A affinity chromatography. A representative set of data of the 372
response to rMbST and bST of the mentioned protein A purified antibodies by checker-board 373
titration in the antigen-coated ELISA is displayed in Figure 2, including also one of the 374
generic pAbs (BC8) for comparative purposes. The highest rMbST/bST recognition ratio was 375
observed for pAb MU11, therefore highlighting the superior efficiency of the immunogen 376
based on the rMbST N-terminus-mimicking MAP coupled to KLH over the other strategies 377
used. Despite the fact that suitable amino acid number in MAPs is usually considered to be 378
comprised between 10 and 20 residues [35], the immunization with an rMbST N-terminus 379
dipeptide-mimicking MAP has been proven to be sufficiently immunogenic to induce the 380
production of anti-rMbST antibodies.381
In conclusion, as previously reported by other authors regarding the production of antibodies 382
directed to other targets [33, 36], the immunization with a MAP resulted in a stronger and/or 383
more specific response than that generated by a mimicking monovalent peptide or the 384
complete recombinant protein. According to the results herein presented, the rabbit pAb 385
MU11 was chosen for the development of an anti-rMbST immunoassay. 386
3.3. Competitive immunoassay based on the polyclonal antibody MU11387
Those combinations of antibody dilution/coating antigen (rMbST) affording adequate signal 388
intensity (around 1 absorbance units), as determined by checker-board titration, were selected 389
to perform inhibition experiments using rMbST and bST as competitors. A preliminary 390
experiment was carried out to determine the assay conditions generating the highest 391
inhibition ratios for rMbST. It was found that the introduction of a pre-incubation step of the 392
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antibody and the competitor in combination with  a short period of time for the competitive 393
step provided an improvement of the assay sensitivity (results not shown). Compensation of 394
signal loss due to the reduction of the immunoreactive step time was achieved using a signal 395
amplification system based on a biotinylated secondary antibody and HRP–labeled 396
streptavidin. As shown in Figure 3, a specific response was displayed by the antibody MU11 397
towards rMbST, whereas no inhibition was observed when bST was used as competitor. All 398
of the evaluated combinations afforded very similar inhibition ratios for rMbST, with an 399
estimated IC50 value comprised between 500 and 5000 μg L-1. In order to improve the 400
antibody performance in terms of sensitivity, the pAb was subjected  to a further purification 401
step using an rMbST N-terminus-mimicking synthetic peptide-based affinity procedure. The 402
affinity purification of antibodies produced against rMbST has been previously reported, 403
although in all of the described methods the complete recombinant protein was used with this 404
purpose [16, 17, 21, 25]. The competitive standard curves for rMbST and bST, as well as the 405
assay conditions and parameters obtained using the peptide-purified MU11 pAb in the most 406
sensitive coating antigen/antibody dilution combination are included in Figure 4. By using 407
the peptide-purified fraction of the pAb MU11 the assay sensitivity was greatly improved, 408
being the resulting LOD for rMbST in buffer of 66 μg L-1. This result indicates that antigen-409
based affinity purification is a convenient strategy not only to isolate the immunoglobulin 410
sub-populations directed to a ligand, but also to modulate the overall avidity of a pAb, and 411
thus the assay sensitivity, as those immunoglobulins with the lowest affinity towards the 412
target are removed during the washing step. Levels of rMbST/bST in fresh bovine milk after 413
administration of somatotropin slow release formulations have been reported to be below 5 414
μg L-1 [15, 37], in contrast to plasma or serum, where concentrations up to 120 μg L-1 have 415
been found [13]. Furthermore, common heat treatments to which commercial milk is 416
submitted prior to commercialization, such as pasteurization, reduce up to 90% the 417
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rMbST/bST content [14, 37]. In order to effectively monitor the presence of rMbST in milk 418
samples, further improvement of the MU11-based immunoassay herein presented is therefore 419
required, or alternatively, the production of additional receptors which display the specificity 420
to rMbST shown by pAb MU11, altogether with an increased affinity towards the target. As a 421
first approach, immunization with rMbST-mimicking MAPs bearing longer peptides will be 422
attempted, in order to determine the influence of the length of the displayed subunits in the 423
MAP on the avidity of the produced antibodies. 424
3.4. Cross-reactivity analysis425
The interaction of the peptide-purified MU11 pAb with bST and somatotropins from other 426
species (either native or recombinant; pST and rMeST), BSA, milk bovine proteins 427
(lactoferrin, β-lactoglobulin and casein), as well as bovine proteins displaying a high 428
sequence homology with bST (lactogen and prolactin) was assessed in a cross-reactivity 429
study, using the mentioned molecules as competitors. No recognition was observed to any of 430
the evaluated proteins, with the exception of rMeST, for which a CR value of 5.6% was 431
obtained. The pituitary somatotropins which were not recognized by MU11, bST and pST, 432
lack the N-terminus methionine present in the dipeptide displayed by the immunogen used for 433
the production of the antibody (MF-MAP-SMCC–KLH), finding which points out the crucial 434
role of this residue as antigenic determinant in the antibody-antigen binding event. 435
Comparing the N-terminus amino acid sequence of rMbST (H2N–436
MFPAMSLSGLFANAVLRA–) with that of rMeST (H2N–MFPAMPLSSLFANAVLRA–), 437
whereas both recombinant proteins present the N-terminus methionine, two differences are 438
encountered (highlighted in bold). Given the decreased interaction observed for rMeST with 439
respect to rMbST, serine at position 6 and/or glycine at position 9 appear to be also required 440
for the antibody recognition. Presumably, the additional purification of the antibody using the 441
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rMbST N-terminus-mimicking linear peptide, would have contributed to the selection of 442
immunoglobulins which paratope would better fit an epitope containing these two amino 443
acids, therefore being specific for rMbST. 444
4. Conclusions445
For decades the production of specific antibodies directed towards rMbST has not been 446
successfully accomplished as a consequence of an extremely minor difference (one amino 447
acid) encountered at the N-terminus of both proteins. In this paper, we report the generation 448
of a rabbit pAb displaying a high selectivity towards rMbST in a competitive antigen-coated 449
ELISA format. The immunogen employed for the production of the pAb consisted in an 450
rMbST N-terminus-mimicking synthetic MAP displaying the first two amino acids of rMbST 451
conjugated to the carrier protein KLH. Further purification of the antibody using an rMbST 452
N-terminus-mimicking synthetic linear peptide significantly improved the performance of the 453
antibody. Further work is currently ongoing in order to produce rMbST-specific monoclonal 454
and polyclonal antibodies to efficiently develop an immunoassay that meets the requirements 455
both in terms of specificity and sensitivity to be implemented for the routine screening of 456
rMbST in milk. 457
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Table and Figure captions529
Table 1. Pituitary and commercial recombinant bST specifications.530
Table 2. Polyclonal antibody production.531
Table 3. Summary of the preliminary characterization of the pAbs by antigen-coated ELISA.532
Figure 1. Chemical structure of the rMbST N-terminus-mimicking immunizing synthetic 533
multiple antigen peptide (MAP).534
Figure 2. Recognition towards rMbST and bST coating antigens (4 µg mL-1) displayed by 535
different pAbs.536
Figure 3. Competitive experiment performed with the protein A purified pAb MU11 using 537
bST and rMbST as competitor reagents (empty and filled bars, respectively). rMbST coating 538
antigen concentrations were 1 (■), 2 (■), 4 (■), 8 (■) and 16 (■) µg/mL, and they were 539
combined with the following antibody dilutions: 1/500, 1/500, 1/1000, 1/1500 and 1/2000, 540
respectively. Each value represents the average of three independent experiments.541
Figure 4. Standard curves for rMbST and bST obtained with the peptide-purified pAb 542
MU11. 543
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- Production of polyclonal antibodies directed to recombinant methionyl bovine 548
somatotropin (rMbST)549
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Table 1. Pituitary and commercial recombinant bST specifications
Somatotropin
aa 
length
Molecular 
weight
Position 
1
Position 
1/2
Position 
126/127
bST variant 1 191 21788 Da Ala-c -Phe-d -Val-e
bST variant 2a 191 21802 Da Ala- -Phe- -Leu-f
bST variant 3 190 21717 Da Phe- -Val-
bST variant 4 190 21731 Da Phe- -Leu-
rMbST 
(Posilac®)b 191 21851 Da
Met-g -Phe-
-Leu-
a Majority isoform of pituitary bST. b Commercial recombinant bST most commonly used 
worldwide. c Alanine. d Phenylalanine. e Valine. f Leucine. g Methionine.
557
558
559
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559
Table 2. Polyclonal antibody production
Immunogen Coupling chemistry pAbs
rMbST–KLHa active ester method (–CO2H groups
in rMbST; –NH2 groups in KLH)
BC5, BC6, BC7, BC8
EP091213–KLHb sulfo-SMCC method (–NH2 groups M9, M10
MF-MAP-SMCC–
KLHc
in KLH; –SH group of Cysd in 
peptides)
MU9, MU10e, MU11, 
MU12
a Complete recombinant methionyl bST. b Synthetic rMbST N-terminus-mimicking linear peptide. 
c Synthetic rMbST N-terminus-mimicking multiple antigen peptide. d Cysteine. e This rabbit died 
during the immunization process.
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566
Table 3. Summary of the preliminary characterization of the pAbs by antigen-coated ELISA
Immunogen pAb Binding to rMbST Binding to bST
BC5 +++a +++
BC6 +++ +++
BC7 +++ +++
rMbST–KLH
BC8 +++ +++
M9 + +EP091213–KLH
M10 – –
MU9 + +
MU11 + –
MF-MAP-SMCC–KLH
MU12 +++ +++
a Results corresponding to the analysis of the raw pAbs used without any further purification. 
Binding to coating antigens (rMbST and bST at 1 µg mL-1) corresponding to a 1/500 dilution of the 
pAbs expressed as: (+++) strong (AU ≥ 2); (++) medium (1 ≤ AU < 2); (+) low (0.3 ≤ AU < 1); (–) 
negligible (AU < 0.3). Those pAbs providing a signal intensity for rMbST at least 0.2 UA above 
that observed towards bST have been highlighted in bold.
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